AARD

Aardvark Therapeutics, Inc. Common Stock NASDAQ Listed Feb 13, 2025

Healthcare ·Biotechnology ·US · aardvarktherapeutics.com

$5.61

Mkt Cap $122.4M

52w Low $3.35 15.5% of range 52w High $17.94

50d MA $5.32 200d MA $10.50

P/E (TTM) -1.9x

EV/EBITDA -3.4x

P/B 1.0x

Debt/Equity 0.0x

ROE -54.0%

P/FCF -4.7x

RSI (14) —

ATR (14) —

Beta 5.34

50d MA $5.32

200d MA $10.50

Avg Volume 288.0K

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.

SIC Code

2834

CIK (SEC)

1774857

Phone

858 225 7696

4370 La Jolla Village Drive · San Diego, CA 92122 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 23, 2026	AMC	-0.83	-0.81	+2.1%	4.07	-1.7%	-7.4%	-6.1%	-0.8%	+1.1%	+2.5%	—
Nov 13, 2025	AMC	-0.80	-0.75	+6.1%	10.86	-4.6%	-8.7%	+4.4%	-5.0%	+6.3%	-9.8%	—
Aug 13, 2025	AMC	-0.60	-0.66	-10.0%	11.20	-3.6%	+0.5%	-4.3%	-3.2%	-2.6%	-4.9%	—
May 14, 2025	AMC	-0.67	-0.71	-5.5%	8.74	+20.7%	+4.0%	+8.8%	+5.5%	+5.5%	+1.1%	—
Feb 26, 2025	AMC	-0.41	-0.68	-65.9%	13.11	-1.9%	+2.2%	-5.0%	+0.0%	-5.7%	-5.2%	—
Sep 30, 2024	AMC	—	-0.32	—	—	—	—	—	—	—	—	—
Jun 30, 2024	AMC	—	-2.13	—	—	—	—	—	—	—	—	—
Mar 31, 2024	AMC	—	-0.17	—	—	—	—	—	—	—	—	—
Dec 31, 2023	AMC	—	-0.21	—	—	—	—	—	—	—	—	—
Sep 30, 2023	AMC	—	-0.22	—	—	—	—	—	—	—	—	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 24	BTIG	Maintains	Buy → Buy	—	$4.07	$4.00	-1.7%	-7.4%	-6.1%	-0.8%	+1.1%	+2.5%
Mar 2	HC Wainwright & Co.	Downgrade	Buy → Neutral	—	$12.49	$5.98	-52.1%	-56.2%	-10.4%	+15.1%	+1.8%	+1.9%
Mar 2	Stifel	Downgrade	Buy → Hold	—	$12.49	$5.98	-52.1%	-56.2%	-10.4%	+15.1%	+1.8%	+1.9%
Mar 2	RBC Capital	Downgrade	Outperform → Sector Perform	—	$12.49	$5.98	-52.1%	-56.2%	-10.4%	+15.1%	+1.8%	+1.9%
Mar 2	Oppenheimer	Maintains	Outperform → Outperform	—	$12.49	$5.98	-52.1%	-56.2%	-10.4%	+15.1%	+1.8%	+1.9%
Mar 2	Morgan Stanley	Downgrade	Overweight → Equal Weight	—	$12.49	$5.98	-52.1%	-56.2%	-10.4%	+15.1%	+1.8%	+1.9%
Mar 2	BTIG	Maintains	Buy → Buy	—	$12.49	$5.98	-52.1%	-56.2%	-10.4%	+15.1%	+1.8%	+1.9%
Feb 10	BTIG	Maintains	Buy → Buy	—	$13.48	$13.46	-0.1%	-6.5%	+0.5%	-3.1%	-1.5%	+2.9%
Feb 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$12.65	$12.65	+0.0%	+6.6%	-6.5%	+0.5%	-3.1%	-1.5%
Nov 14	RBC Capital	Maintains	Outperform → Outperform	—	$10.86	$10.36	-4.6%	-8.7%	+4.4%	-5.0%	+6.3%	-9.8%
Sep 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.23	$11.40	+1.5%	+1.9%	+6.4%	+4.1%	+4.4%	+3.4%
Aug 28	BofA Securities	Maintains	Buy → Buy	—	$8.99	$9.18	+2.1%	-5.6%	-2.2%	+6.7%	-7.7%	+3.8%
Aug 14	RBC Capital	Maintains	Outperform → Outperform	—	$11.20	$10.80	-3.6%	+0.5%	-4.3%	-3.2%	-2.6%	-4.9%
May 15	RBC Capital	Maintains	Outperform → Outperform	—	$8.74	$10.55	+20.7%	+4.0%	+8.8%	+5.5%	+5.5%	+1.1%
Apr 1	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$7.51	$7.50	-0.1%	+10.4%	+12.8%	-7.1%	-6.1%	-2.7%
Apr 1	RBC Capital	Maintains	Outperform → Outperform	—	$7.51	$7.50	-0.1%	+10.4%	+12.8%	-7.1%	-6.1%	-2.7%
Mar 27	BofA Securities	Maintains	Buy → Buy	—	$9.42	$10.28	+9.1%	-5.5%	-13.0%	-3.0%	+10.4%	+12.8%

Data updated apr 24, 2026 10:08am · Source: massive.com